A new role for PHD in chemotherapy.
Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity in normal organs.
Department of Medical Oncology and State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Rui-hua
RH
Xu
Peng
P
Huang
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018390:Gene Targeting; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D009369:Neoplasms / Q000188:drug therapy*; D011393:Procollagen-Proline Dioxygenase / Q000378:metabolism*
D000970:Antineoplastic Agents; D011393:Procollagen-Proline Dioxygenase; C490189:Egln1 protein, mouse; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases